<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4606">
  <stage>Registered</stage>
  <submitdate>3/09/2014</submitdate>
  <approvaldate>3/09/2014</approvaldate>
  <nctid>NCT02232425</nctid>
  <trial_identification>
    <studytitle>IX-01 Effect on Intravaginal Ejaculatory Latency Time (IELT) and Patient Reported Outcomes in Men With Premature Ejaculation (PE)</studytitle>
    <scientifictitle>An 8-Week, Double-Blind, Placebo-Controlled Parallel Group Study to Evaluate the Effect of IX-01 on Intravaginal Ejaculatory Latency Time (IELT) and Patient Reported Outcomes in Men With Lifelong Premature Ejaculation</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>IX-0103</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Premature Ejaculation</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Complications of newborn</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Childbirth and postnatal care</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Fetal medicine and complications of pregnancy</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Renal and Urogenital</conditioncode1>
      <conditioncode2>Other renal and urogenital disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Other reproductive health and childbirth disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - IX-01
Treatment: drugs - Placebo

Experimental: Drug: IX-01 - Two to four 200 mg capsules administered orally, 1-6 hours prior to sexual activity

Placebo Comparator: Placebo - Two to four capsules administered orally, 1-6 hours prior to sexual activity


Treatment: drugs: IX-01


Treatment: drugs: Placebo


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Mean fold change in geometric Mean IELT - IX-01 versus placebo</outcome>
      <timepoint>Last 4 weeks of treatment compared to baseline</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of participants rating their PE as better or much better, on the Clinical Global Impression of Change (CGIC) scale</outcome>
      <timepoint>Baseline to the end of treatment (approximately 8 weeks)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of participants with greater than or equal to (=) 2.5 fold increase in IELT</outcome>
      <timepoint>Last 4 weeks of treatment compared to baseline</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change in arithmetic IELT - IX-01 versus placebo</outcome>
      <timepoint>Last 4 weeks of treatment compared to baseline</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change in score on control of timing of ejaculation - Reported in e-diary</outcome>
      <timepoint>Last 4 weeks of treatment compared to baseline</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change in score on ejaculation-related personal distress - Reported in e-diary</outcome>
      <timepoint>Last 4 weeks of treatment compared to baseline</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of participants with = 1 category of improvement in satisfaction with sexual intercourse, on the Premature Ejaculation Profile (PEP) questionnaire</outcome>
      <timepoint>Baseline to 8 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of participants with = 1 category of improvement in control over ejaculation during sexual intercourse on the PEP questionnaire</outcome>
      <timepoint>Baseline to 8 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of participants with = 1 category of improvement in ejaculation-related distress on the PEP questionnaire</outcome>
      <timepoint>Baseline to 8 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of participants with = 1 category of improvement in ejaculation-related interpersonal difficulty on the PEP questionnaire</outcome>
      <timepoint>Baseline to 8 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Proportion of participants with = 2 category increase in control and = 1 category decrease in personal distress on a Patient Reported Outcome (PRO) measure</outcome>
      <timepoint>Baseline to 8 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of intercourse attempts lasting greater than (&gt;) 1 minute</outcome>
      <timepoint>Last 4 weeks of treatment compared to baseline</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence of treatment-emergent adverse events</outcome>
      <timepoint>Start of Treatment to end of study (approximately 10 weeks)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  In stable (= 6 months) heterosexual relationship

          -  Have life-long (primary) premature ejaculation

          -  Have premature ejaculation confirmed by IELT less than or equal to (=) 1 minute on =
             75% attempts at sexual intercourse

          -  Meet other aspects of the International Society for Sexual Medicine (ISSM) definition
             for lifelong PE, including inability to delay ejaculation on all or nearly all vaginal
             penetrations and negative personal consequences such as distress, bother and
             frustration

          -  Willing to attempt intercourse at least 4 times during run-in period and at least 8
             more times during double-blind part of the study

          -  Not planning pregnancy with his partner and he is willing to use contraception (unless
             not of child-bearing potential, e.g., surgically sterilised)

          -  Willing to limit use of alcohol on days in which they take study drug (not more than
             three drinks, where one drink is defined as a 12 ounce (oz), 360 milliliter (mL)
             bottle of beer, a 5 oz (150 mL) glass of wine, or a 1Â½ oz (45 mL distilled spirits)

          -  Capable of giving written informed consent</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Male</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  An IELT value = 2 minutes during run-in period

          -  Less than (&lt;) 4 attempts at sexual intercourse during run-in (screening may be
             extended or patient may be rescreened if there are extenuating circumstances)

          -  A rating of control of ejaculation as fair, good, or very good on the PEP
             questionnaire prior to study

          -  Co-existing Erectile Dysfunction - International Index of Erectile Dysfunction (IIEF)
             erectile function domain &lt; 22 during run-in

          -  Concomitant use of Phosphodiesterase 5 (PDE5) inhibitors, intracavernosal injections,
             penile implants, Selective Serotonin Reuptake Inhibitors (SSRI's) or
             Serotonin-Norepinephrine Reuptake Inhibitors (SSNRI's), tricyclic antidepressants (for
             example (e.g.) clomipramine), monoamine oxidase inhibitors, alpha blockers, 5 alpha
             reductase inhibitors (including propecia for hair loss), topical anaesthetics, and/or
             tramadol

          -  History (last 6 months) of use of Botox or similar product to treat premature
             ejaculation

          -  Unwilling to stop other treatments for premature ejaculation (including but not
             limited to pharmacological, herbal, multiple condoms, psychosexual treatment, prior
             masturbation)

          -  Other sexual disorder of patient or partner that could interfere with results

          -  Current active sexually transmitted disease

          -  Major medical condition of patient that could interfere with ability to have sexual
             activity and or require hospital treatment

          -  Body Mass Index (BMI) &gt; 40 kg/m2

          -  Participation in a clinical drug trial anytime during the 30 days prior to screening

          -  Human Immunodeficiency Virus (HIV) or hepatitis B

          -  History of clinically significant prostate disease

          -  History of myocardial infarction, coronary bypass surgery, coronary artery
             angioplasty, unstable angina, clinically evident congestive heart failure, cardiac
             pacemaker, or cerebrovascular accident

          -  Cardiac arrhythmia: significant cardiac arrhythmia shown on Electrocardiogram (ECG),
             or a known or suspected history of significant cardiac arrhythmias within last six
             months

          -  History of congenital QT prolongation and/ corrected QT (QTc) interval &gt; 450
             milliseconds (msec) using the Bazett formula

          -  Mean systolic cuff blood pressure (BP) &gt; 140 millimeter of mercury (mmHg), as assessed
             by up to three measurements taken in sequence within 5-10 minutes of last measure

          -  Mean diastolic cuff BP &gt; 90 mmHg, as assessed by up to three measurements taken in
             sequence within 5-10 minutes of the last measure

          -  Major psychiatric disease or risk of suicidal tendency as assessed by clinical
             evaluation and Patient Health Questionnaire (PHQ)-9 and Columbia Suicide Assessment

          -  PHQ-9 questionnaire total score &gt; 9 and/or score &gt; 0 for question 9 of PHQ-9, and/or
             suicidal ideation or behavior as assessed by Columbia Suicide Assessment

          -  Clinically significant abnormal laboratory function test results (including liver
             enzymes &gt; 2 x Upper Limit of Normal (ULN) or bilirubin &gt; 1.5 x ULN)

          -  Taking Cytochrome P450 3A4 (CYP3A4) inducers, or moderate and potent CYP3A4 inhibitors</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2 />
    <masking3 />
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>88</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/10/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,WA</recruitmentstate>
    <hospital>Australian Centre for Sexual Health - Saint Leonards</hospital>
    <hospital>Keogh Institute for Medical Research - Nedlands</hospital>
    <postcode>2065 - Saint Leonards</postcode>
    <postcode>6009 - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Louisiana</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Rhode Island</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Ixchelsis Limited</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>New England Research Institutes</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>Novotech (Australia) Pty Limited</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>ICON plc</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Commercial sector/Industry</othercollaboratortype>
      <othercollaboratorname>PHT Corporation</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine the effectiveness of IX-01 in men with lifelong
      premature ejaculation.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02232425</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Email Katie.George@Ixchelsis.com</name>
      <address>Ixchelsis Limited</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>